Buck Wealth Strategies’s Bio-Rad Laboratories Class A BIO Stock Holding History

Buck Wealth Strategies’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$587	Buy	+2	New	+$567	﹤0.01%	987

Other funds holding BIO

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

Envestnet Asset Management Chicago, Illinois $424B AUM 22.96% 1-Year Est. Return

Buck Wealth Strategies's BIO Position: Q2 2026 in Review

Buck Wealth Strategies opened a new position in Bio-Rad Laboratories Class A (BIO) in Q2 2026: 2 shares worth $587. The stake represents ﹤0.01% of the portfolio and ranks #987 among its holdings.

190 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

Buck Wealth Strategies held 2 shares of Bio-Rad Laboratories Class A worth $587 as of Q2 2026.
Bio-Rad Laboratories Class A was a new Buck Wealth Strategies position in Q2 2026.
Bio-Rad Laboratories Class A made up ﹤0.01% of Buck Wealth Strategies's portfolio in Q2 2026, its #987 holding.
190 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Buck Wealth Strategies's 13F filing for Q2 2026, filed 30 Jul 2026.